Abstract: The present invention relates to Proteinase K variants having a modified amino acid sequence of wild-type Proteinase K amino acid sequence, the wild-type amino acid sequence comprising a first loop region, a second loop region, a third loop region, a fourth loop region, a fifth loop region and a sixth loop region; wherein the modified amino acid sequence comprises different amino acids than that occurring in wild-type Proteinase K (i.e., substitution) at specifically identified positions in one or more of the loop regions whereby the Proteinase K variant has decreased adsorption to, and increased hydrolysis of, an insoluble substrate as compared to the wild-type Proteinase K. The present invention also relates to DNA sequences encoding such Proteinase K variants. The present invention also relates to compositions comprising such Proteinase K variants for cleaning a variety of surfaces.

Abstract: An enzyme having carbonyl reduction activity of reducing a carbonyl compound asymmetrically to produce an optically active alcohol, a DNA coding the enzyme, a plasmid having the DNA, a transformant which is a cell transformed with the plasmid, and a production method of an optically active alcohol using the enzyme and/or the transformed cell are provided.

Abstract: An enzymatic RNA molecule which specifically cleaves a herpes simplex virus mRNA molecule.

Abstract: The present invention relates to subtilisin BPN′ variants having a modified amino acid sequence of wild-type BPN′ amino acid sequence, the wild-type amino acid sequence comprising a first loop region, a second loop region, a third loop region, a fourth loop region and a fifth loop region; wherein the modified amino acid sequence comprises different amino acids than that occurring in wild-type subtilisin BPN′ (i.e., substitution) at specifically identified positions in one or more of the loop regions whereby the BPN′ variant has decreased adsorption to, and increased hydrolysis of, an insoluble substrate as compared to the wild-type subtilisin BPN′. The present invention also relates to the genes encoding such subtilisin BPN′ variants. The present invention also relates to compositions comprising such subtilisin BPN′ variants for cleaning a variety of surfaces.

Abstract: A chimeric polypeptide has a first and a second polypeptide chain chemically linked via 1 to 3 cysteine-based disulfide bridges. The first polypeptide chain consists of 1 to 3 cysteines and 4 to 12 basic amino acids preferably selected from the group consisting of arginine, lysine and ornithine. The second polypeptide chain consists of 1 to 3 cysteines and 4 to 12 acidic amino acids selected from the group consisting of glutamate and aspartate. Each polypeptide chain is linked at its C- or N-terminus to a biologically active compound, and is useful as a multimeric pharmaceutical agent.

Abstract: The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the proteins of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the proteins of the present invention, and methods of identifying modulators of the proteins of the present invention.

Abstract: The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the kinase peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the kinase peptides, and methods of identifying modulators of the kinase peptides.

Abstract: The invention provides human aspartic proteases (NHAP) and polynucleotides which identify and encode NHAP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of NHAP.

Abstract: An enzymatic RNA molecule which specifically cleaves a herpes simplex virus mRNA molecule.

Abstract: Human choline acetyltransferase polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for the treatment of cognitive and neurological deficiencies or mental disturbances such as degenerative nervous system disorders, for example, Alzheimer's Disease, ALS and other cholinergic defects, and antagonists for treating Parkinson's Disease and other disorders relating to an over-expression of acetylcholine. Also disclosed are diagnostic methods for detecting a mutation in the human Choline Acetyltransferase nucleic acid sequence.

Abstract: The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the drug-metabolizing enzyme peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the drug-metabolizing enzyme peptides, and methods of identifying modulators of the drug-metabolizing enzyme peptides.

Abstract: The present invention relates to isolated DNA sequences which code for the expression of plant 1-deoxy-D-xylulose-5-phosphate reductoisomerase protein, such as the sequence presented in SEQ ID NO:1 which encodes a 1-deoxy-D-xylulose-5-phosphate reductoisomerase protein from peppermint (Mentha x piperita). Additionally, the present invention relates to isolated plant 1-deoxy-D-xylulose-5-phosphate reductoisomerase protein. In other aspects, the present invention is directed to replicable recombinant cloning vehicles comprising a nucleic acid sequence which codes for a plant 1-deoxy-D-xylulose-5-phosphate reductoisomerase, to modified host cells transformed, transfected, infected and/or injected with a recombinant cloning vehicle and/or DNA sequence of the invention.

Abstract: The invention provides human cyclic nucleotide phosphodiesterases (HSPDE10A) and polynucleotides which identify and encode HSPDE10A. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists and methods for diagnosing or treating disorders associated with expression of HSPDE10A.

Abstract: The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the kinase peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the kinase peptides, and methods of identifying modulators of the kinase peptides.

Abstract: The present invention relates to recombinant DNA which encodes the BpmI restriction endonuclease as well as BpmI methyltransferase, expression of BpmI restriction endonuclease from E. coli cells containing the recombinant DNA. BpmI endonuclease is a fusion of two distinct elements with a possible structural domains of restriction-methylation-specificity (R-M-S). This domain organization is analogous to the type I restriction-modification system with three distinct subunits, restriction, methylation, and specificity (R, M, and S). Because BpmI is quite distinct to other type IIs restriction enzymes, it is proposed that BpmI belongs to a subgroup of type II restriction enzymes called type IIf (f stands for fusion of restriction-modification-specificity domains). The Type IIf group of restriction enzyme includes Eco57I, BpmI, GsuI, BseRI and some other restriction enzymes that cut downstream sequences at long distance, 10-20 bp downstream of recognition sequence, such as MmeI (N20/N18)).

Abstract: The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the kinase peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the kinase peptides, and methods of identifying modulators of the kinase peptides.

Abstract: The present invention provides amino acid sequences of polypeptides that are encoded by genes within the human genome, the dehydrogenase polypeptides of the present invention. The present invention specifically provides isolated polypeptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the dehydrogenase polypeptides, and methods of identifying modulators of the dehydrogenase polypeptides.

Abstract: Disclosed are methods and compositions for identifying, monitoring and treating premalignant and malignant conditions in a human subject. The present invention further discloses methods and compositions for determining cells undergoing apoptosis, and for increasing the efficacy of a cancer therapy. The methods involve the use of apurinic/apyrimidinic endonuclease (APE), independently, as a marker for (pre)malignant conditions and for apoptosis. Also described are polyclonal antibody preparations for use in methods for detecting APE and methods for modulating expression susceptibility of cells to apoptosis.

Abstract: The present invention relates to recombinant DNA which encodes the BstYI restriction endonuclease as well as BstYI methyltransferase, expression of BstYI restriction endonuclease and M.BstYI in E. coli cells containing the recombinant DNA. It also relates to methods for purification of the recombinant BstYI restriction endonuclease and BstYI methyltransferase.

Abstract: The invention discloses a novel thermostable D-hydantoinase, and relates to the nucleic acid sequence, amino acid sequence and vector constructs of the enzyme. The thermostable D-hydantoinase of the invention shows about 45%-70% identity in amino acid sequence with other D-hydantoinases. The thermostable D-hydantoinase of the invention converts 5′-substituted D-hydantoinase to the corresponding N-carbamoyl-D- and/or -L-&agr;/&bgr;-amino acids, and retains at least 50% activity after 30 days at 50° C. In addition, the enzyme activity can also enhanced by certain divalent cations.